Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma in colon or rectum~* Age \>18~* Metastatic colorectal cancer progressed after chemotherapy regimens containing fluoropyrimidines, oxaliplatin and irinotecan.~* KRAS mutation in primary tumour or metastasis.~* Measurable disease according to RECIST~* ECOG performance status 0, 1 or 2~* Adequate function of liver, kidneys and bone marrow measured by biochemistry (max. 2 weeks before enrolment)~* EDTA clearance: Uncorrected GFR \> 45 ml/min.~* Neutrophilocytes ≥1.5 x 10\^9/l, leukocytes ≥3.0 x 10\^9/l, thrombocytes ≥100x10\^9/l~* ALAT ≤ 3 x upper normal value (ULN), bilirubin ≤ 3 x upper normal value, Aptt and INR normal (or 2-3 at AC treatment). (ALAT and basic phosphatase ≤ 5 x upper normal value in case of liver metastases).~* Blood samples and paraffin embedded tissue from primary tumour and/or metastases for translational research.~* Fertile men and women (women \<2 year after last menstruation) must use efficient birth control.~* Signed informed consent.~Exclusion Criteria:~* Clinically significant other concurrent disease making the patient unfit for participation in the study according to the investigator.~* Other malignant disease within 5 years prior to study enrolment, except from planocellular and basal cell carcinomas in the skin or carcinoma-in-situ cervix.~* Other experimental treatment within 30 days prior to treatment start.~* Pregnant or breastfeeding women.~* Clinical or radiological signs of CNS metastases.~* Planned radiation of target lesions.~* Concurrent vaccination against yellow fever.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).